MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC boosted its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 18.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 488,805 shares of the company’s stock after acquiring an additional 77,590 shares during the quarter. TimesSquare Capital Management LLC owned about 0.78% of MoonLake Immunotherapeutics worth $29,519,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MLTX. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at about $717,000. TD Asset Management Inc lifted its position in shares of MoonLake Immunotherapeutics by 101.1% during the 3rd quarter. TD Asset Management Inc now owns 200,390 shares of the company’s stock valued at $11,422,000 after acquiring an additional 100,750 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of MoonLake Immunotherapeutics during the 3rd quarter worth approximately $293,000. Victory Capital Management Inc. grew its holdings in shares of MoonLake Immunotherapeutics by 773.4% in the 3rd quarter. Victory Capital Management Inc. now owns 182,977 shares of the company’s stock worth $10,430,000 after acquiring an additional 162,027 shares during the period. Finally, Arizona State Retirement System purchased a new position in MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $293,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock traded down $1.03 during trading on Wednesday, hitting $42.63. The company’s stock had a trading volume of 125,713 shares, compared to its average volume of 440,025. The stock’s fifty day moving average is $46.03 and its 200 day moving average is $50.77. MoonLake Immunotherapeutics has a 1-year low of $24.31 and a 1-year high of $64.98. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of -56.09 and a beta of 1.29.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, research analysts anticipate that MoonLake Immunotherapeutics will post -1.11 EPS for the current fiscal year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, insider Kristian Reich sold 10,000 shares of the stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $62.43, for a total value of $624,300.00. Following the transaction, the insider now directly owns 130,071 shares of the company’s stock, valued at approximately $8,120,332.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 62,810 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $55.00, for a total transaction of $3,454,550.00. Following the transaction, the chief executive officer now directly owns 3,043,619 shares of the company’s stock, valued at $167,399,045. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Kristian Reich sold 10,000 shares of the stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $62.43, for a total transaction of $624,300.00. Following the completion of the sale, the insider now directly owns 130,071 shares of the company’s stock, valued at approximately $8,120,332.53. The disclosure for this sale can be found here. Insiders have sold a total of 166,981 shares of company stock worth $9,490,674 in the last quarter. 15.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on MLTX shares. William Blair reissued an “outperform” rating and issued a $92.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, February 26th. Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Wednesday. Wedbush restated an “outperform” rating and set a $92.00 target price on shares of MoonLake Immunotherapeutics in a research report on Wednesday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Wednesday. Finally, The Goldman Sachs Group initiated coverage on MoonLake Immunotherapeutics in a research report on Tuesday, April 2nd. They set a “neutral” rating and a $62.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $74.46.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.